Indications and uses
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat
tablet melts in mouth. Can be taken with or without water. Age Dose adults and children 6 years and over 1 tablet daily; do not use more than 1 tablet daily children under 6 ask a doctor consumers who have liver or kidney disease ask a doctor
Loratadine 10 mg
Antihistamine
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies:
if you have ever had an allergic reaction to this product or any of its ingredients
liver or kidney disease. Your doctor should determine if you need a different dose.
do not use more than directed. Taking more than recommended may cause drowsiness.
an allergic reaction to this product occurs. Seek medical help right away.
ask a health professional before use.
In case of overdose, get medical help or contact a Poison Control Center right away.
| Age | Dose |
|---|---|
adults and children 6 years and over | 1 tablet daily; do not use more than 1 tablet daily |
children under 6 | ask a doctor |
consumers who have liver or kidney disease | ask a doctor |
anhydrous citric acid, aspartame, colloidal silicon dioxide, corn syrup solids, crospovidone, magnesium stearate, mannitol, microcrystalline cellulose, modified starch, natural and artificial flavors, sodium bicarbonate
anhydrous citric acid, aspartame, butylated hydroxyanisole, colloidal silicon dioxide, corn syrup solids, crospovidone, dextrin, ferric oxides, magnesium stearate, maltodextrin, mannitol, microcrystalline cellulose, modified starch, natural and artificial flavors, sodium bicarbonate
call weekdays from 9 AM to 5 PM EST at 1-800-ALAVERT (1-800-252-8378)
The product packaging shown below represents a sample of that currently in use. Additional packaging may also be available.
ALAVERT allergy Fresh Mint
Loratadine Orally Disintegrating Tablet, 10 mg, Antihistamine
18 Orally Disintegrating Tablets
TASTES GREAT!
Melts in your Mouth!
Non-Drowsy* Allergy Relief
*When taken as directed. See Drug Facts Panel.
24 HOUR Relief of
Compare to Claritin †& SAVE!
†Claritin is a registered trademark of Schering Corporation

ALAVERT allergy Citrus Burst
Loratadine Orally Disintegrating Tablet, 10 mg, Antihistamine
18 Orally Disintegrating Tablets
TASTES GREAT!
Melts in your Mouth!
Non-Drowsy* Allergy Relief
*When taken as directed. See Drug Facts Panel.
24 HOUR Relief of
Compare to Claritin† & SAVE!
†Claritin is a registered trademark of Schering Corporation

| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0573-2620-06 | EA - Each | 0573-2620 | a426c267-75e5-4ee7-9ccb-d16f65916fb8 | 1 | 2013-02-11 |
| 0573-2620-19 | EA - Each | 0573-2620 | 803dfd04-b25f-4194-9168-06ac17863609 | 1 | 2012-07-24 |
| 0573-2620-30 | EA - Each | 0573-2620 | 7da8de28-0e7a-453a-81e4-006ec98783a2 | 1 | 2014-01-04 |
| 0573-2620-65 | EA - Each | 0573-2620 | 526cf195-dcb5-4dc1-ab35-715787f1e3d7 | 1 | 2012-07-24 |
| 0573-2621-19 | EA - Each | 0573-2621 | 1fcf8024-13e4-4f89-8a06-70c42d581338 | 1 | 2014-01-04 |
| 0573-2621-65 | EA - Each | 0573-2621 | 88b60682-6817-47c6-87b5-205696e5dc03 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| LORATADINE | ACTIVE INGREDIENT | 7AJO3BO7QN | 7 | |
| LORATADINE | ACTIVE MOIETY | 7AJO3BO7QN | 7 | |
| ANHYDROUS CITRIC ACID | INACTIVE INGREDIENT | XF417D3PSL | 7 | |
| ASPARTAME | INACTIVE INGREDIENT | Z0H242BBR1 | 7 | |
| BUTYLATED HYDROXYANISOLE | INACTIVE INGREDIENT | REK4960K2U | 7 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | 7 | |
| CORN SYRUP | INACTIVE INGREDIENT | 9G5L16BK6N | 7 | |
| CROSPOVIDONE | INACTIVE INGREDIENT | 68401960MK | 7 | |
| FERRIC OXIDE RED | INACTIVE INGREDIENT | 1K09F3G675 | 7 | |
| ICODEXTRIN | INACTIVE INGREDIENT | 2NX48Z0A9G | 7 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 7 | |
| MALTODEXTRIN | INACTIVE INGREDIENT | 7CVR7L4A2D | 7 | |
| MANNITOL | INACTIVE INGREDIENT | 3OWL53L36A | 7 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 7 | |
| SODIUM BICARBONATE | INACTIVE INGREDIENT | 8MDF5V39QO | 7 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0573-2620 | 0573-2620-19, 0573-2620-01, 0573-2620-65, 0573-2620-71 |
| 0573-2621 | 0573-2621-65, 0573-2621-19, 0573-2621-13 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| ICODEXTRIN | ICODEXTRIN | 2NX48Z0A9G | SHAMPOO / TOPICAL | 5 %w/w | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / TOPICAL | 6 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, COATED / ORAL | 177.7 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 78 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, EXTENDED RELEASE / ORAL | 1246 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER, FOR SUSPENSION / ORAL | 120 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CREAM / TOPICAL | NA | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | AEROSOL, FOAM / TOPICAL | 6 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE, COATED PELLETS / ORAL | 456 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | CAPSULE / ORAL | 2169 mg | ||
| CORN SYRUP | CORN SYRUP | 9G5L16BK6N | SOLUTION / ORAL | 750 mg/5ml | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, ORALLY DISINTEGRATING / ORAL | 1800 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | FILM, SOLUBLE / ORAL | 2 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET / BUCCAL | 360 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION / SUBCUTANEOUS | 675 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, ORALLY DISINTEGRATING / ORAL | 187 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | GUM, CHEWING / BUCCAL | 240 mg | ||
| CORN SYRUP | CORN SYRUP | 9G5L16BK6N | SUSPENSION, EXTENDED RELEASE / ORAL | 1500 mg/5ml | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | FILM, SOLUBLE / ORAL | 7 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, EXTENDED RELEASE / ORAL | 7 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | LOTION / TOPICAL | NA | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | CAPSULE, EXTENDED RELEASE / ORAL | 3 mg | ||
| MALTODEXTRIN | MALTODEXTRIN | 7CVR7L4A2D | POWDER, FOR SUSPENSION / ORAL | 8000 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | TABLET, CHEWABLE / ORAL | 195 mg | ||
| ICODEXTRIN | ICODEXTRIN | 2NX48Z0A9G | LOTION / TOPICAL | NA | ||
| BUTYLATED HYDROXYANISOLE | BUTYLATED HYDROXYANISOLE | REK4960K2U | CAPSULE, LIQUID FILLED / ORAL | 4 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / BUCCAL | 17.5 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | RING / VAGINAL | 2 mg | ||
| ICODEXTRIN | ICODEXTRIN | 2NX48Z0A9G | TABLET, EXTENDED RELEASE / ORAL | 6 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, DELAYED RELEASE / ORAL | 3.2 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SPRAY / TOPICAL | 0.01 %w/w | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | TABLET / SUBLINGUAL | 8 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | INSERT / VAGINAL | 69 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 1000 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 658 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CREAM / TOPICAL | NA | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SOLUTION / TOPICAL | 4.35 %w/v | ||
| BUTYLATED HYDROXYANISOLE | BUTYLATED HYDROXYANISOLE | REK4960K2U | OINTMENT / VAGINAL | 0.02 %w/w | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, SOLUTION / INTRAMUSCULAR | 25 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SUSPENSION/ DROPS / OPHTHALMIC | 0.05 %w/v | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | TABLET / SUBLINGUAL | 36 mg | ||
| ASPARTAME | ASPARTAME | Z0H242BBR1 | TABLET, FOR SUSPENSION / ORAL | 15 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TROCHE / ORAL | 300 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | SOLUTION / ORAL | 3900 mg | ||
| BUTYLATED HYDROXYANISOLE | BUTYLATED HYDROXYANISOLE | REK4960K2U | LOTION / TOPICAL | NA | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, COATED / ORAL | 0.12 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | POWDER / RESPIRATORY (INHALATION) | 0.13 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE / ORAL | 5 mg | ||
| CORN SYRUP | CORN SYRUP | 9G5L16BK6N | TABLET / ORAL | 14.07 mg | ||
| BUTYLATED HYDROXYANISOLE | BUTYLATED HYDROXYANISOLE | REK4960K2U | CREAM / TOPICAL | 2 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SOLUTION / ORAL | 336 mg | ||
| CELLULOSE, MICROCRYSTALLINE | MICROCRYSTALLINE CELLULOSE | OP1R32D61U | TABLET, CHEWABLE / ORAL | 1725 mg | ||
| BUTYLATED HYDROXYANISOLE | BUTYLATED HYDROXYANISOLE | REK4960K2U | CAPSULE / ORAL | 4 mg | ||
| ANHYDROUS CITRIC ACID | ANHYDROUS CITRIC ACID | XF417D3PSL | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 35 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION, GEL FORMING, EXTENDED RELEASE / OPHTHALMIC | 4.35 %w/w | ||
| MALTODEXTRIN | MALTODEXTRIN | 7CVR7L4A2D | FILM, SOLUBLE / ORAL | 19 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SPRAY / NASAL | 41.5 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | INSERT / VAGINAL | 129 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N021375-001 | ALAVERT | LORATADINE | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 011fe1cb6892… | ||
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 31067a03dcf5… | ||
| 2025-08-23 18:47 UTC | 2025-08 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 6a471c1ec25d… | ||
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | fd3edfee7708… | ||
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | b8a1b40f171c… | ||
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 03ed91905a0d… | ||
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 2680178bc6a6… | ||
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 5bbf6a4d5a75… | ||
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | d8e5a09893c0… | ||
| 2024-10-29 15:01 UTC | 2024-10 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | d06236e962d9… | ||
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 79d66fd596c7… | ||
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 301d65b070ca… | ||
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 1e350fbaab3a… | ||
| 2024-05-31 18:47 UTC | 2024-05 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 8072bd15b7f6… | ||
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 5c6f7cd8ea54… | ||
| 2022-04-08 23:34 UTC | 2022-04 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 5d02ea3f76ae… | ||
| 2022-04-04 05:41 UTC | 2022-04 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 4b0b4de00fa7… | ||
| 2019-12-13 00:20 UTC | 2019-12 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 74a2ff9319b5… | ||
| 2022-03-09 01:35 UTC | 2022-03 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | bb7c543d1eb4… | ||
| 2021-12-28 21:50 UTC | 2021-12 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 782e0a99824c… | ||
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 87673890dc5c… | ||
| 2021-03-12 10:30 UTC | 2021-03 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 5aa47cf7b7d7… | ||
| 2020-12-22 03:56 UTC | 2020-12 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 8869cabd3fbd… | ||
| 2020-11-12 02:37 UTC | 2020-11 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | c0c555d07b60… | ||
| 2019-12-14 00:12 UTC | 2019-12 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 3f01610625f2… | ||
| 2019-09-15 20:21 UTC | 2019-09 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | b00525d2431f… | ||
| 2019-07-19 19:46 UTC | 2019-07 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | ea99ee380514… | ||
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 6a51e52b5d6a… | ||
| 2024-02-18 07:12 UTC | 2024-02 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 1c564ffb4f44… | ||
| 2023-12-20 04:57 UTC | 2023-12 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | ea1830bbd6c7… | ||
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | a72a2bbeb626… | ||
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 9b2671bbb829… | ||
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | a67488948f0b… | ||
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 3f0d92c62455… | ||
| 2023-05-13 08:27 UTC | 2023-05 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 053a50430f4f… | ||
| 2023-01-26 05:58 UTC | 2023-01 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 3bdfa0b2c4d7… | ||
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | 3a93d1ddd44b… | ||
| 2022-10-28 04:53 UTC | 2022-10 | N021375-001 | ALAVERT | 10MG | TABLET, ORALLY DISINTEGRATING / ORAL | 2002-12-19 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 181d3342-4e2f-7aad-e063-6294a90a8d9c | f45af3e4-5dd5-ea0a-c47c-8d68a1249158 | 2024-05-10 | Warnings | f45af3e4-5dd5-ea0a-c47c-8d68a1249158 |
Adverse event summaries are temporarily unavailable. Other product information remains available.